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ORIGINAL ARTICLE
DRD2 co-expression network and a related polygenic index
predict imaging, behavioral and clinical phenotypes linked
to schizophrenia
G Pergola1, P Di Carlo1, E D'Ambrosio1,2, B Gelao1, L Fazio1, M Papalino1, A Monda1, G Scozia1, B Pietrangelo1, M Attrotto1, JA Apud3,
Q Chen2, VS Mattay2,4, A Rampino1,5, G Caforio5, DR Weinberger2,6, G Blasi5 and A Bertolino1,5
Genetic risk for schizophrenia (SCZ) is determined by many genetic loci whose compound biological effects are difﬁcult to
determine. We hypothesized that co-expression pathways of SCZ risk genes are associated with system-level brain function and
clinical phenotypes of SCZ. We examined genetic variants related to the dopamine D2 receptor gene DRD2 co-expression pathway
and associated them with working memory (WM) behavior, the related brain activity and treatment response. Using two
independent post-mortem prefrontal messenger RNA (mRNA) data sets (total N= 249), we identiﬁed a DRD2 co-expression pathway
enriched for SCZ risk genes. Next, we identiﬁed non-coding single-nucleotide polymorphisms (SNPs) associated with co-expression
of this pathway. These SNPs were associated with regulatory genetic loci in the dorsolateral prefrontal cortex (Po0.05). We
summarized their compound effect on co-expression into a Polygenic Co-expression Index (PCI), which predicted DRD2 pathway
co-expression in both mRNA data sets (all Po0.05). We associated the PCI with brain activity during WM performance in two
independent samples of healthy individuals (total N= 368) and 29 patients with SCZ who performed the n-back task. Greater
predicted DRD2 pathway prefrontal co-expression was associated with greater prefrontal activity and longer WM reaction times (all
corrected Po0.05), thus indicating inefﬁcient WM processing. Blind prediction of treatment response to antipsychotics in two
independent samples of patients with SCZ suggested better clinical course of patientswith greater PCI (total N= 87; Po0.05). The
ﬁndings on this DRD2 co-expression pathway are a proof of concept that gene co-expression can parse SCZ risk genes into
biological pathways associated with intermediate phenotypes as well as with clinically meaningful information.
Translational Psychiatry (2017) 7, e1006; doi:10.1038/tp.2016.253; published online 17 January 2017
INTRODUCTION
Many genome-wide studies have demonstrated that complex
heritable diseases such as schizophrenia (SCZ) are associated with
numerous common genetic variants with small effects on suscep-
tibility across heterogeneous populations. Risk variants are not
randomly interspersed in the genome, but cluster in selective
molecular pathways.1,2 Therefore, molecular pathways may be
more informative than any individual molecule or molecular event
per se.3 As genetic variation in risk genes translates into biological
risk associated with measurable phenotypes,4 identifying common
molecular pathways that predict the phenotypes of interest may
help elucidating the basis of genetic liability.
Many risk loci for SCZ are associated with the modulation of
gene expression.3,5 A cardinal principle of the organization of
molecular pathways is that gene expression is co-regulated and
pathways are likely co-expressed.6 This may be also the case of
SCZ genes.7 Therefore, risk genes for SCZ may be linked through
co-expression pathways.8,9
Here we studied brain-speciﬁc gene co-expression as a principle
to identify molecular pathways of risk genes and detect further
genes related with SCZ as ‘guilty by association’. With respect to
SCZ risk, the DRD2 gene coding for the D2 dopamine receptor is
an optimal candidate to investigate the genetic architecture of
molecular pathways affected in patients with SCZ. A long-standing
hypothesis holds that dopaminergic dysfunctional regulation in
subcortical areas and in the prefrontal cortex (PFC) is a key
pathophysiological mechanism of SCZ.10,11 For example, working
memory (WM) deﬁcits, among the core symptoms in SCZ, are
related with alterations of PFC activity.12–19 Moreover, PFC activity
during WM is predicted by midbrain dopamine,20 striatal
dopamine21 and by reductions of amphetamine-induced release
of prefrontal dopamine binding to D2 receptors in SCZ.22 Critically,
research by the Psychiatric Genomic Consortium (PGC) supported
the notion that the DRD2 gene coding for the D2 dopaminergic
receptor is associated with risk for SCZ.23 DRD2 is not only related
to SCZ risk, but genetic variation within this gene has been linked
with phenotypes related to SCZ and its treatment.24–27 Consistent
with studies showing that D2 dopaminergic receptors are involved
in WM,28 functional genetic variants in DRD2 have also been
associated with WM performance and related cortical activity in
healthy subjects and in patients with SCZ.21,27 For example, a non-
coding single-nucleotide polymorphism (SNP) of DRD2, rs1076560,
modulates alternative splicing of the D2 dopaminergic receptor
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transcript into two major isoforms (D2 long, D2L, and D2 short,
D2S), likely affecting neuronal activity.27 However, DRD2 single-
SNP associations explain only a small fraction of risk for SCZ and
related phenotypes.21,27
We investigated the compound association between SNPs
approximating in vivo the transcription levels of a gene set co-
expressed with D2L and phenotypes of relevance to SCZ. We
focused on D2L in the PFC because it is mainly found at the post-
synaptic terminal,29 its expression is altered in the PFC of patients
with SCZ,13 and we were interested in the modulation of activity
of neuronal populations receiving dopaminergic afferents during
WM, a mechanism that is altered in SCZ.22 Furthermore, D2L is
targeted by antipsychotic medications.29,30 To achieve our aim, we
performed four consecutive steps (Figure 1). First, we identiﬁed
the co-expression gene set of D2L from human post-mortem
PFC.31 Second, we identiﬁed the association of independent
genetic variants of the genes included in the gene set with
expression of the whole gene set. Third, we combined these
genetic variants into a Polygenic Co-expression Index (PCI)
designed to index the genetic component of gene transcription
co-regulation and validated this index in an independent post-
mortem data set. Fourth, we associated our PCI with brain activity
and behavioral performance during WM, that is, D2L-dependent
and key intermediate phenotypes for SCZ,31 and response to
treatment with antipsychotics which target D2 signaling in SCZ.
Based on prior evidence,22 we hypothesized that genetic variants
associated with greater co-expression of D2L and its gene set
would also be associated with greater BOLD signal in the PFC
during WM and poorer behavioral performance. In patients with
SCZ, we investigated the preservation of the PCI–BOLD signal
Figure 1. Concept of the study. DLPFC, dorsolateral prefrontal cortex; SNP, single-nucleotide polymorphism.
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relationships and assessed the sensitivity and speciﬁcity of the PCI
as predictor of treatment outcome. Previous ﬁndings reported
that the T allele of rs1076560, which is associated with a greater
D2L/D2S ratio in the PFC,2 is also associated with greater symptom
improvement in patients with SCZ15 Therefore, we hypothesized
that greater D2L gene set co-expression in the PFC indexed by the
PCI predicted greater clinical response.
MATERIALS AND METHODS
Participants
Table 1 summarizes the demographic data of the subjects included in all
experiments. After receiving a complete description of the study, all
participants in the clinical and the imaging studies provided written
informed consent following the guidelines of the Declaration of Helsinki.
Protocols and procedures were approved by the ethics committee of the
University of Bari and by the institutional review board of the National
Institute of Health, Bethesda, MD, USA.
Network identiﬁcation
We used the publicly available Braincloud data set5 (http://braincloud.jhmi.
edu/) for a genome-wide Weighted Genes Co-expression Network
Analysis.32 The sample included 199 observations (demographics in
Table 1). We preprocessed the gene expression matrix to factor out
confounding variables, including demographics. The ﬁrst principal
component of the DRD2 gene set (module eigengene, ME) served to
track the simultaneous variation of the whole gene set. We correlated this
co-expression measure with DRD2 expression levels.32 To investigate the
biological functions that may be subserved by this ensemble of co-
expressed genes, we computed gene ontology enrichment analysis using
AmiGO2 (http://amigo.geneontology.org/amigo/landing). Finally, we
assessed enrichment of the gene set for the loci associated with SCZ risk
by the Psychiatric Genomic Consortium (PGC23 with a hypergeometric test
(SI Materials and Methods).
SNP association study
We performed a gene set-wide association study of SNPs with the ME. The
sample size of our post-mortem data set is probably small for a genetic
association study, and co-expression is most likely a phenotypic trait with
complex heritability, much like SCZ. Power calculations in genetic
association studies have been shown to depend on many factors,
including heritability of the trait, the proportion of variance explained by
the genotyped SNPs, the total number of SNPs, the proportion of SNPs
with no effect on the trait, the total sample size and the P-value threshold
for SNP selection.33 The heritability of expression quantitative trait loci
(eQTLs) is extremely variable and appears to be comparable between
cis- and trans-eQTLs (co-eQTLs fall in the latter category34). Nevertheless,
there is evidence of high replicability of eQTLs both with stringent and
more lenient thresholds of signiﬁcance.35 These ﬁndings suggest that,
beside statistical signiﬁcance, genetic signals in the study of gene
expression may be found beyond the threshold for corrected or nominal
signiﬁcance, as is also the case of complex clinical traits.36
Based on these considerations, we ﬁrst tested for co-eQTLs that would
survive stringent Bonferroni correction; then, we employed more
permissive statistics for our association to minimize false-negative ﬁndings
and performed internal cross-validations and independent replication to
minimize type I errors. Through this procedure, we aimed at identifying an
ensemble of SNPs that, together, predict co-expression. We used eight
SNPs associated with the ﬁrst principal component of gene set co-
expression with Po0.005 to compute the PCI. As a common method to
select SNPs for subsequent inclusion in polygenic scores consists in
increasing the number of SNPs until the proportion of variance plateaus,37
we also tested whether such an approach selected the same set of eight
SNPs with P o0.005 (SI Materials and Methods). We interrogated Haploreg
v4.1 (http://archive.broadinstitute.org/mammals/haploreg/haploreg.php)
to gain information on the possible regulatory functions of these SNPs.38
Then, we computed the PCI by assigning a weight to each genotype of
each SNP based on the expression proﬁle within different genotypic
groups.39 The greater the PCI, the greater is the messenger RNA expression
level of that individual. We cross-validated the PCI and assessed ethnicity
and population stratiﬁcation effects, as well as age effects (SI Materials and
Methods).
We used the publicly available BrainEAC data set40 to replicate the
association of the PCI with D2L co-expression in the frontal cortex. From
this data set, we selected the probes of all genes included in the D2L co-
expression pathway and preprocessed the data as above reported. The
sample included 50 Caucasian participants.40 We computed the PCI of each
individual and associated it with the ME using Pearson’s correlation.
Imaging study. We recruited 124 healthy unrelated Caucasian adults from
the region of Apulia, Italy (demographics in Table 1), for a functional
magnetic resonance imaging (fMRI) experiment and genotyped them for
the SNPs included in the PCI. We used the n-back task to probe WM.41
Stimuli consisted of numbers (1–4) shown in random sequence and
displayed at the points of a diamond-shaped box. There was a non-
memory-guided control condition (0-back) that required subjects to
identify the stimulus currently seen. As memory load increased, the task
required the recollection of a stimulus seen one (1-back) or two (2-back)
stimuli before, while keeping on encoding incoming stimuli (SI Materials
and Methods). We tested the association of the PCI with brain activation
using repeated measures analysis of covariance (within-subject factor:
LOAD (1-back, 2-back); covariates: age, gender and handedness; whole-
brain topological false discovery rate-corrected α= 0.05; extent thresh-
old = 6, that is, 4300 mm3).
We recruited a second fMRI sample of 244 Caucasian healthy volunteers
as part of the NIMH Clinical Brain Disorders Branch ‘Sibling Study’ (Table 1).
These participants performed the same 2-back fMRI task described above
and were genome-wide genotyped (SI Materials and Methods42). The
effect of the PCI on BOLD response was tested using robust linear
models43–45 with age, gender and handedness as covariates of no interest.
We performed one-tailed t-tests using as regions of interest the clusters
associated with the PCI in the ﬁrst healthy sample. We used MarsBar
(http://marsbar.sourceforge.net/) to extract the percent signal change and
corrected for the number of tests (false discovery rate46).
For the fMRI study on the clinical cohort, we recruited 29 Caucasian
patients with SCID diagnosis of SCZ from the region of Apulia, Italy
(Table 1). Genotyping and fMRI protocols matched the procedures
followed for the ﬁrst fMRI healthy sample.
Behavioral analyses. In the ﬁrst healthy fMRI sample, we investigated
behavioral performance (accuracy and reaction time) during the WM task
in the scanning session (SI Materials and Methods). We analyzed accuracy,
that is, percent of correct responses, and reaction times with repeated
Table 1. Demographic data in all studies reported
Sample name Sample size Female (male) [ratio] Age mean± s.d. years Age range (years)
Braincloud 199 60 (139) [0.43] 32.3± 20 0–78
BrainEAC 50 15 (35) [0.43] 57± 19 20–91
First healthy fMRI study 124 54 (70) [0.77] 27.5± 6.6 19–48
Second healthy fMRI study 244 132 (112) [1.20] 29.4± 8.4 18–55
fMRI patients study 29 3 (26) [0.12] 29.3± 7.0 15–42
First clinical study 47 8 (39) [0.21] 28.7± 7.0 16–42
Second clinical study 40 11 (29) [0.38] 27.4± 6.5 18–40
Abbreviation: fMRI, functional magnetic resonance imaging.
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measures analysis of covariance (within-subject factor: LOAD (1-back, 2-
back)) and PCI as a predictor. As we were testing two measures, we set the
threshold for signiﬁcance at α= 0.025 (Bonferroni correction). In the clinical
fMRI sample, we analyzed behavioral performance following the same
procedures employed for the ﬁrst fMRI sample.
Pharmacogenetics. The ﬁrst clinical cohort in the pharmacogenetic study
included 47 Caucasian patients with SCZ (Structured Clinical Interview for
DSM (SCID) diagnosis)26 recruited from the region of Apulia, Italy (Table 1).
Treatment response was computed as the difference in the total Positive
And Negative Syndrome Scale (PANSS) core between baseline and
treatment end.
The second cohort consisted of 40 patients with SCZ with history of
inadequate treatment response recruited at the Clinical Brain Disorders
Branch SCZ inpatient research unit at the National Institutes of Health
Clinical Center, Bethesda, MD, USA.26 Treatment response was deﬁned
as the difference between symptoms severity at the end of placebo
treatment and severity at the end of drug treatment.15 The clinical protocols
used in the pharmacogenetic study for both samples have been described in
detail previously26 (see Supplementary Table 2 for clinical data).
We ﬁrst performed an association study to investigate the direction of the
PCI treatment response relationship using Spearman’s Rho; then, we assessed
the potency of the PCI as predictor of treatment response in comparison with
pharmacological doses and off-medication symptom severity using Receiver
Operating Characteristic curves (SI Materials and Methods).
RESULTS
Identiﬁcation of the D2L gene set
We identiﬁed a co-expression gene set of 85 genes including the D2L
transcript (Supplementary Table 1). Its ﬁrst principal component (ME)
explained 32.5% of the variance. D2L expression levels positively
correlated with ME (R2 =0.4). The D2L co-expression pathway was
enriched for the ontologies DNA packaging (GO:0006323, corrected
P-value=0.002), negative regulation of dopamine secretion
(GO:0033602, corrected P-value=0.004) and response to nicotine
(GO:0035094, corrected P-value=0.03); notably, some of these results
may be affected by our choice of the DRD2 module as a candidate
gene set. Besides DRD2, this gene set included three genes
associated with SCZ based on PGC2 (GATAD2A, GALNT10 and
ZSCAN23). The enrichment of the gene set for protein-coding genes
located in the genome-wide association study loci associated with
SCZ by PGC223 was signiﬁcant (hypergeometric test, P=0.029).
Identiﬁcation of co-eQTLs associated with co-expression of the
whole D2L module
Eight independent SNPs located in the genes included in the
module were associated with co-expression of the whole gene set,
that is, the ME (Table 2). The ﬁrst SNP, rs2486064, survives even
very stringent statistics using Bonferroni correction for multiple
comparisons (corrected P= 0.0033). Table 2 shows that these SNPs
are not strong predictors of SCZ status in the PGC2 work.23 Five
out of these eight non-coding SNPs modify regulatory motifs47
and two out of eight have been previously recognized as trans-
eQTLs.48 As an ensemble, these SNPs are strongly associated with
gene expression regulation in the dorsolateral prefrontal cortex
Haploreg v4.1, P= 0.00049, SI Appendix). We used these SNPs to
compute the PCI and to verify its correlation with expression of
the whole gene set (as per deﬁnition of the PCI; R2 = 0.38) and D2L
transcriptional levels (t198 = 5.8, R
2 = 0.14, P= 2.9 × 10− 8;
Supplementary Figure 1). These effects were not affected either
by population stratiﬁcation or by age (Supplementary Table 3; SI
Results). Multiple cross-validations performed using different
procedures uniformly supported the association between co-
expression of the gene set and the PCI (Supplementary Figures 2
and 3).
As in spite of all in silico validations it cannot be deﬁnitively
ruled out that our ﬁndings were related with peculiarities of the
speciﬁc sample analyzed, for example, with ethnicity, we
replicated the association between the PCI and the gene set
using an independent data set (BrainEAC40). BrainEAC included 80
out of the 85 probes of the D2L gene set above identiﬁed and was
not affected by ethnicity effects because it only included
Caucasian subjects. The correlation between the PCI and gene
set co-expression replicated in the same direction (Pearson’s
R= 0.23, one-tailed P= 0.05). The association was strongest for
highest quality observations (for example, with RNA Integrity
Number (RIN)46, R= 0.38, one-tailed P= 0.028; Supplementary
Figure 4). This is relevant because all Braincloud data had RIN47,
thus we found a signiﬁcant association in spite of non-overlapping
probes, of partly degraded messenger RNAs and of ethnicity
differences.
Biological validation of the PCI by means of association with
system-level phenotypes: imaging study
In the ﬁrst healthy sample, activity in the fronto-parietal WM
network correlated positively with the PCI surviving whole-brain
peak-level correction for multiple comparisons (topological false
discovery rate qo0.05; Figure 2 and Table 3). Individuals with
greater PCI and greater predicted D2L gene set co-expression
levels had greater bilateral activation in the WM brain network
during task performance, that is, they were less efﬁcient in
processing WM information. There was no signiﬁcant negative
correlation with the PCI or LOAD×PCI interaction on brain activity.
Further analyses supporting the robustness of these results are
reported in Supplementary Tables 3–4 and Supplementary Figures
5–6.
In the second healthy sample, we used the clusters identiﬁed in
the ﬁrst sample to extract the signal change which we associated
to the PCI. We found signiﬁcant correlations between the PCI and
percent signal change in the left anterior middle frontal gyrus
(BA10), and in the right inferior parietal lobule (BA40; Table 3). Also
in patients, brain activity correlated with the PCI (Supplementary
Table 2. SNPs associated with the ﬁrst principal component of D2L gene set expression
Rank Marker Locus Genea Gene name Uncorrected P-value MAF PGC P-value
1 rs2486064 1q32.1 CHIT1 Chitinase 1 5.0 × 10− 6 0.22 0.088
2 rs6902039 6p22.3 GPLD1 Glycosylphosphatidyl inositol-speciﬁc phospholipase D1 4.6 × 10− 4 0.23 0.48
3 rs851436 2p24.1 OSR1 Odd-skipped related 1 1.0 × 10− 3 0.48 0.77
4 rs9297283 8q22.2 POP1 Processing of precursor 1, ribonuclease P/MRP subunit 1.0 × 10− 3 0.20 0.33
5 rs12940715 17q25.1 SDK2 Sidekick cell adhesion molecule 2 1.7 × 10− 3 0.20 0.050
6 rs1805453 17p13.2 DHX33 DEAH (Asp–Glu–Ala–His) Box Polypeptide 33 2.8 × 10− 3 0.34 0.054
7 rs11213916 11q22.3 BTG4 B-cell translocation gene 4 3.0 × 10− 3 0.30 0.50
8 rs1037791 7p21.1 AGR2 Anterior gradient 2 3.2 × 10− 3 0.31 0.94
Abbreviations: MAF, minor allele frequency in the Braincloud sample; PGC, Psychiatric Genomics Consortium; SNP, single-nucleotide polymorphism. aThe Gene
column reports the genes included in the D2L gene set. SNPs fall in a ± 100 kbp window from the set genes. P-values refer to the association with diagnosis of
schizophrenia.
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Figure 7). Hence, the PCI–BOLD association was preserved in
patients with SCZ.
Behavioral results
In the ﬁrst healthy fMRI sample, repeated measures analysis of
covariance (within-subject factor LOAD (1-back, 2-back)) on WM
accuracy and reaction times revealed a signiﬁcant LOAD×PCI
interaction on reaction times surviving Bonferroni correction
(F1,120 = 6.9, P= 0.01). Post hoc regressions were non-signiﬁcant for
1-back (t120 = 0.12, adjusted R
2 =− 0.008, P= 0.91) but yielded a
signiﬁcant ﬁt for 2-back (Supplementary Figure 6; t120 = 2.3,
adjusted R2 = 0.033, P= 0.024). Greater PCI was related with longer
reaction times at 2-back (Supplementary Figure 8), supporting the
imaging ﬁndings and the interpretation of reduced efﬁciency in
these individuals. No other signiﬁcant effects or interactions
involved the PCI (SI Results). The same analysis on behavioral data
of the clinical fMRI sample yielded no signiﬁcant effects or
interactions (all P40.05).
Clinical translation of the PCI by means of association with
response to treatment with antipsychotics
The correlation between clinical improvement (difference in
PANSS total score between baseline and end point) and PCI was
positive and signiﬁcant in the ﬁrst clinical sample (N= 47, ρ= 0.39;
P= 0.007; Supplementary Figure 9). Results replicated in the
second clinical sample (PANSS total score, N= 40, ρ= 0.27, one-
tailed P= 0.047). Greater PCI was associated with greater clinical
response. Then, we pooled the two samples (N= 87) and tested
the blind prediction of treatment response based on the PCI,
which was signiﬁcant (area under the curve (AUC) = 0.63, P= 0.043;
Supplementary Figure 10). Similarly, off-medication symptoms
(AUC= 0.62, P= 0.048) signiﬁcantly predicted treatment response,
whereas dose adjustment was a marginally signiﬁcant predictor
(AUC= 0.61, P= 0.079).
DISCUSSION
We believe the present results provide the ﬁrst proof of concept
that the co-expression context of SCZ risk genes, for example,
DRD2, affects system-level and clinical phenotypes. Although
previous studies indexed gene expression based on cis-genetic
markers,39,49 here we detected co-expression trans-eQTLs
(co-eQTLs) to predict gene co-expression using a network
approach. This data-driven, bias-free procedure identiﬁed a
molecular pathway of convergence of some genes associated
with risk for SCZ. The D2L network recapitulates part of the
complex neurobiology of SCZ and other systems level pheno-
types, including WM performance and related brain activity.
Genes co-expressed with D2L
We found that the variability of system-level phenotypes is closely
associated with a shared component between co-expressed
genes. Indeed, the statistics of the association between the PCI
and imaging phenotypes outperform prior reports on the effect of
genetic variants associated with DRD2.26,27 Moreover, the effect of
the PCI survived when we co-varied for DRD2 rs1076560 genotype
Figure 2. Discovery and replication functional magnetic resonance imaging results. (a) First sample. Signiﬁcant clusters associated with the
positive slope of the Polygenic Co-expression Index (PCI) at topological false discovery rate-corrected q-value o0.05 (cluster extent= 6). (b)
Second sample. Scatter plots of the % signal change in two clusters with signiﬁcant positive correlation with the PCI in the second sample. The
regression line is blue, 95% conﬁdence intervals for the ﬁt are gray. See Table 3 for the exact statistics and localization of clusters ‘A’ and ‘D’.
Left in the ﬁgure is left in the brain.
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(SI Results). Interestingly, our gene set included genes previously
associated with biochemical pathways relevant to SCZ, for
example, calcium- and cannabinoid-mediated transmission like
CACNA2D4 (ref. 50) and CNR1.51 The gene set also includes genes
not mentioned in the latest PGC2 publication, but associated with
SCZ in previous genome-wide association studies, such as
CALHM3.52 Interestingly, one of the set genes associated with
SCZ, GATAD2A, ranked fourth for intramodular connectivity, hence
belonging to a group of highly connected genes (hubs) within the
identiﬁed network. GATAD2A is involved in gene silencing and is
associated with histones.53 Accordingly, the gene set includes
further histone-related genes (HIST1H1E, HIST1H3G and
HIST2H2AC) and several of the SNPs included in the PCI are
associated with histone functions (SI Appendix; see also the SI
Discussion for more information on the SNPs identiﬁed). Histone
proteins have been highlighted in a recent trans-diagnostic gene
set analysis of the genetic architecture of psychiatric disorders.23
Because of the data-driven nature of the approach, genes
associated by prior literature with D2 dopamine receptors, for
example, by physical interaction, may end up in different clusters
when building a network. Therefore, not all genes relevant to D2L-
mediated signaling are included in the gene set studied here.
However, a tenet of co-expression analyses is that co-expressing
genes are co-regulated in terms of transcription, for example, they
may be targeted by the same repressors/enhancers or si/miRNA. It
is also important to note that the network we identiﬁed is a model
of co-expression, and does not necessarily represent gene co-
regulation. For example, gene expression patterns vary as a
function of many variables, such as age,5 ethnicity and cell type.
Here we clustered genes based on their expression patterns
corrected for confounding variables. The SI Materials and Methods
includes additional information on age and ethnicity effects (SI
Results).
Because of the relatively small sample size of post-mortem data
sets for a genetic association study, we used permissive
procedures for co-eQTL detection. Then, we cross-validated the
SNP weights and also the SNP selection within Braincloud, we
replicated the effects in BrainEAC, and we also cross-validated the
SNPs entering the PCI in the fMRI experiment. Together, these
validation steps and the ﬁndings obtained in multiple indepen-
dent data sets across multiple biological scales support the idea
that the SNPs identiﬁed here are valid and modulate the D2L co-
expression pathway. It is remarkable that eight common SNPs
weighted for their molecular effects on gene co-expression
accounted for a sizable proportion of variance in prefrontal
activation and signiﬁcantly predicted treatment outcome in
patients with SCZ (SI Discussion).
The SNPs associated with the D2L co-expression gene set that
we identiﬁed have not been previously reported for their
association with DRD2 or with psychiatric or cognitive phenotypes,
except for rs1037791 that has been associated with the openness
subscale of the big ﬁve personality traits.54 However, the ﬁrst-
ranked SNP, which even survived Bonferroni correction for
multiple comparisons, is intergenic between two paralog genes,
CHIT1 and CHI3L1. Both genes code for stress-induced chitinases
and prior evidence associated brain CHI3L1 expression with
SCZ.55,56 Genetic variants in this intergenic region such as
rs4950928 have been associated with SCZ.57,58 This SNP is located
upstream of CHI3L1 where also rs2486064 is located (linkage
disequilibrium: r2 = 0.35, D′= 1). This regulatory region likely
interacts with speciﬁc transcription factors.57,58 CHI3L1 expression
has been proposed to be relevant to SCZ because of its
association with the AKT1–GSK3β pathway,58 which is also
associated with the cyclic AMP-independent pathway of DRD2.59
The present evidence suggests a further candidate molecular
mechanism of action of genetic variants located in this region in
SCZ, that is, regulation of a DRD2 co-expression gene set.T
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The association of the D2L co-expression PCI with prefrontal
activity and WM performance
Dopamine D2 receptor signaling is a critical modulator of WM. The
present ﬁndings suggest that individuals bearing genotypes
associated with increased simultaneous expression of the D2L
gene set manifest greater PFC activity as well as longer reaction
times during WM. These ﬁndings suggest that increased expres-
sion of the D2L co-expression gene set predisposes to less
efﬁcient WM processing, a well-established intermediate risk-
associated phenotype for SCZ.31 These results are also consistent
with a large body of studies demonstrating that pharmacological
manipulation of dopamine D2R is associated with WM perfor-
mance and with prefrontal activity measured with BOLD fMRI.41,60
Critically, they are consistent with a recent study reporting that
greater prefrontal D2 PET binding is positively correlated with
prefrontal activity during WM.22 Finally, these ﬁndings are
consistent with several reports from our group suggesting that
the T allele of rs1076560, associated with greater D2L/D2S ratio
compared with the G allele, is also associated with inefﬁcient
prefrontal activity during WM.21,27,41 The present ﬁndings extend
this earlier work by showing that the co-expression gene set
identiﬁed by our network analysis is associated with genetic
background outside the DRD2 gene. Such genetic variation is in
turn associated with intermediate phenotypes of SCZ.
The role of D2L and its co-expression gene set in treatment
response to antipsychotics in patients with SCZ
D2 dopaminergic receptor is the main target of antipsychotic
medications29,30 and previous evidence indicated that T-carriers
for rs1076560 beneﬁt more from antipsychotic treatment than
other patients with SCZ.26 Consistently, here we show that greater
predicted expression of a D2L co-expression gene set is associated
with greater clinical improvement. We found this association not
only in drug-naive/drug-free patients but also in patients with
history of inadequate treatment response. The strength of the
prediction based on the PCI compared favorably with clinical
predictors such as pharmacological dose. Results suggest that SCZ
patients with greater genetically determined availability of a main
target of antipsychotics are predisposed to better treatment
response.
CONCLUSIONS
The present ﬁndings suggest that a D2L co-expression gene set
enriched for protein-coding genes associated with schizophrenia
modulates PFC function during WM and response to D2
antagonist antipsychotic drugs. The genetic variants detected in
this study were not associated with diagnosis, but were located in
regulatory genetic loci. In other words, genetic variation
modulating molecular pathways of SCZ risk genes may recapitu-
late part of the variance of SCZ-related phenotypes in healthy and
clinical populations.
CONFLICT OF INTEREST
GP is the academic supervisor of a collaborative research project with Hoffman-La
Roche, Ltd, which supports his and AR's salary. The remaining authors declare no
conﬂict of interest.
ACKNOWLEDGMENTS
We are grateful to Dr Andrew Jaffe, Dr Richard Straub, Dr Gianluca Ursini (Lieber
Institute for Brain Development), Dr Nicola Amoroso (Department of Physics,
University of Bari Aldo Moro) and Dr Silvia Torretta (Department of Basic Medical
Science, Neuroscience and Sense Organs, University of Bari Aldo Moro) for helpful
methodological insights. Data acquisition was made possible by Rita Masellis, Dr
Paolo Taurisano, Tiziana Quarto, Dr Raffaella Romano, Dr Annamaria Porcelli, Dr
Marina Mancini, Linda Antonucci and Dr Silvia Torretta (Department of Basic Medical
Science, Neuroscience, and Sense Organs, University of Bari Aldo Moro). Finally, we
gratefully acknowledge the work by Dr Pierluigi Selvaggi, Alessandra Raio, Roberta
Passiatore and Dalila Albergo (Department of Basic Medical Science, Neuroscience,
and Sense Organs – University of Bari Aldo Moro), who contributed to data analysis.
This research has been funded by a ‘Capitale Umano ad Alta Qualiﬁcazione’ grant by
Fondazione Con Il Sud and by the NARSAD grant (number: 28935) awarded to
Alessandro Bertolino, by the NIMH Clinical Brain Disorders Branch ‘Sibling Study’
protocol 95-M-0150 awarded to Daniel R. Weinberger, and by the Lieber Institute for
Brain Development. The funding sources had no role in the design and conduct of
the study; collection, management, analysis and interpretation of the data;
preparation, review or approval of the manuscript; and decision to submit the
manuscript for publication.
REFERENCES
1 Kendler KS. What psychiatric genetics has taught us about the nature of psy-
chiatric illness and what is left to learn. Mol Psychiatry 2013; 18: 1058–1066.
2 Network and Pathway Analysis Subgroup of Psychiatric Genomics Consortium
Psychiatric genome-wide association study analyses implicate neuronal, immune
and histone pathways. Nat Neuroscience 2015; 18: 199–209.
3 Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuro-
pathology: on the matter of their convergence. Mol Psychiatry 2005; 10: 40–68.
4 Insel TR. The NIMH Research Domain Criteria (RDoC) Project: precision medicine
for psychiatry. Am J Psychiatry 2014; 171: 395–397.
5 Colantuoni C, Lipska BK, Ye T, Hyde TM, Tao R, Leek JT et al. Temporal dynamics
and genetic control of transcription in the human prefrontal cortex. Nature 2011;
478: 519–523.
6 Gaiteri C, Ding Y, French B, Tseng GC, Sibille E. Beyond modules and hubs: the
potential of gene coexpression networks for investigating molecular mechanisms
of complex brain disorders. Genes Brain Behav 2014; 13: 13–24.
7 Hauberg ME, Roussos P, Grove J, Borglum AD, Mattheisen M. Analyzing the role of
microRNAs in schizophrenia in the context of common genetic risk variants. JAMA
Psychiatry 2016; 73: 369–377.
8 Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of
genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863–14868.
9 Ramani AK, Li Z, Hart GT, Carlson MW, Boutz DR, Marcotte EM. A map of human
protein interactions derived from co-expression of human mRNAs and their
orthologs. Mol Syst Biol 2008; 4: 180.
10 Weinberger DR, DeLisi LE, Perman GP, Targum S, Wyatt RJ. Computed tomo-
graphy in schizophreniform disorder and other acute psychiatric disorders. Arch
Gen Psychiatry 1982; 39: 778–783.
11 Abi-Dargham A. Schizophrenia: overview and dopamine dysfunction. J Clin Psy-
chiatry 2014; 75: e31.
12 Bertolino A, Caforio G, Petruzzella V, Latorre V, Rubino V, Dimalta S et al. Prefrontal
dysfunction in schizophrenia controlling for COMT Val158Met genotype and
working memory performance. Psychiatry Res 2006; 147: 221–226.
13 Bertolino A, Esposito G, Callicott JH, Mattay VS, Van Horn JD, Frank JA et al.
Speciﬁc relationship between prefrontal neuronal N-acetylaspartate and activa-
tion of the working memory cortical network in schizophrenia. Am J Psychiatry
2000; 157: 26–33.
14 Callicott JH, Ramsey NF, Tallent K, Bertolino A, Knable MB, Coppola R et al.
Functional magnetic resonance imaging brain mapping in psychiatry: methodo-
logical issues illustrated in a study of working memory in schizophrenia. Neu-
ropsychopharmacology 1998; 18: 186–196.
15 Goldman-Rakic PS. Working memory dysfunction in schizophrenia. J Neuro-
psychiatry Clin Neurosci 1994; 6: 348–357.
16 Lee J, Park S. Working memory impairments in schizophrenia: a meta-analysis.
J Abnorm Psychol 2005; 114: 599–611.
17 Manoach DS. Prefrontal cortex dysfunction during working memory performance
in schizophrenia: reconciling discrepant ﬁndings. Schizophr Res 2003; 60: 285–298.
18 Schwarz E, Tost H, Meyer-Lindenberg A. Working memory genetics in schizo-
phrenia and related disorders: an RDoC perspective. Am J Med Genet B Neu-
ropsychiatr Genet 2016; 171: 121–131.
19 Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK et al.
Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001; 50:
825–844.
20 Meyer-Lindenberg A, Kohn PD, Kolachana B, Kippenhan S, McInerney-Leo A,
Nussbaum R et al. Midbrain dopamine and prefrontal function in humans:
interaction and modulation by COMT genotype. Nat Neurosci 2005; 8: 594–596.
21 Bertolino A, Taurisano P, Pisciotta NM, Blasi G, Fazio L, Romano R et al. Genetically
determined measures of striatal D2 signaling predict prefrontal activity during
working memory performance. PloS One 2010; 5: e9348.
22 Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R
et al. Deﬁcits in prefrontal cortical and extrastriatal dopamine release in
DRD2 pathway predicts schizophrenia phenotypes
G Pergola et al
7
Translational Psychiatry (2017), 1 – 8
schizophrenia: a positron emission tomographic functional magnetic resonance
imaging study. JAMA Psychiatry 2015; 72: 316–324.
23 Schizophrenia Working Group of the Psychiatric Genomics Consortium Biological
insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511:
421–427.
24 Kaalund SS, Newburn EN, Ye T, Tao R, Li C, Deep-Soboslay A et al. Contrasting
changes in DRD1 and DRD2 splice variant expression in schizophrenia and
affective disorders, and associations with SNPs in postmortem brain. Mol Psy-
chiatry 2014; 19: 1258–1266.
25 Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical
response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 2010;
167: 763–772.
26 Blasi G, Selvaggi P, Fazio L, Antonucci LA, Taurisano P, Masellis R et al. Variation in
dopamine D2 and serotonin 5-HT2A receptor genes is associated with working
memory processing and response to treatment with antipsychotics. Neu-
ropsychopharmacology 2015; 40: 1600–1608.
27 Zhang Y, Bertolino A, Fazio L, Blasi G, Rampino A, Romano R et al. Polymorphisms
in human dopamine D2 receptor gene affect gene expression, splicing, and
neuronal activity during working memory. Proc Natl Acad Sci USA 2007; 104:
20552–20557.
28 Kellendonk C, Simpson EH, Polan HJ, Malleret G, Vronskaya S, Winiger V et al.
Transient and selective overexpression of dopamine D2 receptors in the striatum
causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006; 49:
603–615.
29 Usiello A, Baik JH, Rouge-Pont F, Picetti R, Dierich A, LeMeur M et al. Distinct
functions of the two isoforms of dopamine D2 receptors. Nature 2000; 408:
199–203.
30 Richtand NM, Welge JA, Logue AD, Keck PE Jr, Strakowski SM, McNamara RK.
Dopamine and serotonin receptor binding and antipsychotic efﬁcacy. Neu-
ropsychopharmacology 2007; 32: 1715–1726.
31 Callicott JH, Egan MF, Mattay VS, Bertolino A, Bone AD, Verchinksi B et al.
Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact
siblings of patients with schizophrenia. Am J Psychiatry 2003; 160: 709–719.
32 Zhang B, Horvath S. A general framework for weighted gene co-expression net-
work analysis. Stat Appl Genet Mol Biol 2005; 4: Article17.
33 Dudbridge F. Power and predictive accuracy of polygenic risk scores. PLoS Genet
2013; 9: e1003348.
34 Yang S, Liu Y, Jiang N, Chen J, Leach L, Luo Z et al. Genome-wide eQTLs and
heritability for gene expression traits in unrelated individuals. BMC Genomics
2014; 15: 13.
35 Wright FA, Sullivan PF, Brooks AI, Zou F, Sun W, Xia K et al. Heritability and
genomics of gene expression in peripheral blood. Nat Genet 2014; 46: 430–437.
36 Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF et al.
Common polygenic variation contributes to risk of schizophrenia and bipolar
disorder. Nature 2009; 460: 748–752.
37 Maher BS. Polygenic scores in epidemiology: risk prediction, etiology, and clinical
utility. Curr Epidemiol Rep 2015; 2: 239–244.
38 Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal variants, cell
types, regulators and target genes for human complex traits and disease. Nucleic
Acids Res 2016; 44: D877–D881.
39 Pergola G, Di Carlo P, Andriola I, Gelao B, Torretta S, Attrotto MT et al. Combined
effect of genetic variants in the GluN2B coding gene (GRIN2B) on prefrontal
function during working memory performance. Psychol Med 2015; 1–16.
40 Trabzuni D, Ryten M, Walker R, Smith C, Imran S, Ramasamy A et al. Quality control
parameters on a large dataset of regionally dissected human control brains for
whole genome expression studies. J Neurochem 2011; 119: 275–282.
41 Gelao B, Fazio L, Selvaggi P, Di Giorgio A, Taurisano P, Quarto T et al. DRD2
genotype predicts prefrontal activity during working memory after stimulation of
D2 receptors with bromocriptine. Psychopharmacology 2014; 231: 2361–2370.
42 Rasetti R, Sambataro F, Chen Q, Callicott JH, Mattay VS, Weinberger DR. Altered
cortical network dynamics: a potential intermediate phenotype for schizophrenia
and association with ZNF804A. Arch Gen Psychiatry 2011; 68: 1207–1217.
43 Holland PaW R. Robust regression using interatively reweighted least-squares.
Commun Stat Theory Methods 1977; 6: 813–827.
44 Huber PJ. Robust regression: asymptotics, conjectures and Monte Carlo. Ann Stat
1973; 1: 799–821.
45 Huber PJ. Robust Statistics. John Wiley & Sons: New York, 1981.
46 Benjamini Y, Hochberg Y. On the adaptive control of the false discovery
fate in multiple testing with independent statistics. J Educ Behav Stat 2000; 25:
60–83.
47 Kheradpour P, Kellis M. Systematic discovery and characterization of regulatory
motifs in ENCODE TF binding experiments. Nucleic Acids Res 2014; 42: 2976–2987.
48 Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J et al. Sys-
tematic identiﬁcation of trans eQTLs as putative drivers of known disease asso-
ciations. Nat Genet 2013; 45: 1238–1243.
49 Gamazon ER, Wheeler HE, Shah KP, Mozaffari SV, Aquino-Michaels K, Carroll RJ
et al. A gene-based association method for mapping traits using reference
transcriptome data. Nat Genet 2015; 47: 1091–1098.
50 Hertzberg L, Katsel P, Roussos P, Haroutunian V, Domany E. Integration of gene
expression and GWAS results supports involvement of calcium signaling in
Schizophrenia. Schizophr Res 2015; 164: 92–99.
51 Colizzi M, Iyegbe C, Powell J, Ursini G, Porcelli A, Bonvino A et al. Interaction
between functional genetic variation of DRD2 and Cannabis use on risk of psy-
chosis. Schizophr Bull 2015; 41: 1171–1182.
52 Ripke S, O'Dushlaine C, Chambert K, Moran JL, Kahler AK, Akterin S et al. Genome-
wide association analysis identiﬁes 13 new risk loci for schizophrenia. Nat Gen
2013; 45: 1150–1159.
53 Walavalkar NM, Gordon N, Williams DC Jr.. Unique features of the anti-parallel,
heterodimeric coiled-coil interaction between methyl-cytosine binding domain 2
(MBD2) homologues and GATA zinc ﬁnger domain containing 2 A (GATAD2A/
p66alpha). J Biol Chem 2013; 288: 3419–3427.
54 Terracciano A, Sanna S, Uda M, Deiana B, Usala G, Busonero F et al. Genome-wide
association scan for ﬁve major dimensions of personality. Mol Psychiatry 2010; 15:
647–656.
55 Chung C, Tallerico T, Seeman P. Schizophrenia hippocampus has elevated
expression of chondrex glycoprotein gene. Synapse 2003; 50: 29–34.
56 Arion D, Unger T, Lewis DA, Levitt P, Mirnics K. Molecular evidence for increased
expression of genes related to immune and chaperone function in the prefrontal
cortex in schizophrenia. Biol Psychiatry 2007; 62: 711–721.
57 Zhao X, Tang R, Gao B, Shi Y, Zhou J, Guo S et al. Functional variants in the
promoter region of Chitinase 3-like 1 (CHI3L1) and susceptibility to schizophrenia.
Am J Hum Genet 2007; 80: 12–18.
58 Yang MS, Morris DW, Donohoe G, Kenny E, O'Dushalaine CT, Schwaiger S et al.
Chitinase-3-like 1 (CHI3L1) gene and schizophrenia: genetic association and a
potential functional mechanism. Biol Psychiatry 2008; 64: 98–103.
59 Blasi G, Napolitano F, Ursini G, Di Giorgio A, Caforio G, Taurisano P et al. Asso-
ciation of GSK-3beta genetic variation with GSK-3beta expression, prefrontal
cortical thickness, prefrontal physiology, and schizophrenia. Am J Psychiatry 2013;
170: 868–876.
60 Kahnt T, Weber SC, Haker H, Robbins TW, Tobler PN. Dopamine D2-receptor
blockade enhances decoding of prefrontal signals in humans. J Neuroscience
2015; 35: 4104–4111.
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative Commons
license, users will need to obtain permission from the license holder to reproduce the
material. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/
© The Author(s) 2017
Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)
DRD2 pathway predicts schizophrenia phenotypes
G Pergola et al
8
Translational Psychiatry (2017), 1 – 8
